Opioids and addiction: Emerging pharmaceutical strategies for reducing reward and opponent processes

Clinical Neuroscience Research

Volumn 5, Issue 2-4, 2005, Pages 103-115

  Bryant, Camron D ^a   Zaki, Paulette A ^a   Carroll, F Ivy ^a   Evans, Christopher J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cannabinoid; Cholecystokinin; Cyclic adenosine monophosphate (cAMP); Morphine; Neurokinin; Opiate; Tolerance; Withdrawal

Indexed keywords

ADENYLATE CYCLASE; ALFENTANIL; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CANNABINOID RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CLONIDINE; COCAINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DIAMORPHINE; FENTANYL; G PROTEIN COUPLED RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; LOFEXIDINE; METHADONE; METHYLPHENIDATE; MORPHINE; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR AFFECTING AGENT; REMIFENTANIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; AVERSIVE BEHAVIOR; BEHAVIOR THERAPY; COGNITIVE THERAPY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG SELECTIVITY; DRUG TOLERANCE; DYSPHORIA; EUPHORIA; EVIDENCE BASED MEDICINE; HUMAN; HYPERALGESIA; HYPOTENSION; MAINTENANCE THERAPY; NEUROMODULATION; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RECEPTOR BINDING; RELAPSE; RESPIRATION DEPRESSION; REVIEW; REWARD; SEDATION; SOMNOLENCE; STRESS; WITHDRAWAL SYNDROME;

EID: 27944445778     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnr.2005.08.006     Document Type: Article

References (158)

1. C.P. Bailey M. Connor Opioids: Cellular mechanisms of tolerance and physical dependence Curr Opin Pharmacol 5 1 2005 60-68
2. S.W. Johnson R.A. North Opioids excite dopamine neurons by hyperpolarization of local interneurons J Neurosci 12 2 1992 483-488
3. M.H. Joseph K. Datla A.M. Young The interpretation of the measurement of nucleus accumbens dopamine by in vivo dialysis: The kick, the craving or the cognition? Neurosci Biobehav Rev 27 6 2003 527-541
4. T.E. Robinson B. Kolb Structural plasticity associated with exposure to drugs of abuse Neuropharmacology 47 Suppl 1 2004 33-46
5. D. Saal Y. Dong A. Bonci R.C. Malenka Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons Neuron 37 4 2003 577-582
6. H.O. Pettit A. Ettenberg F.E. Bloom G.F. Koob Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats Psychopharmacology (Berl) 84 2 1984 167-173
7. R.A. Wise The neurobiology of craving: Implications for the understanding and treatment of addiction J Abnorm Psychol 97 2 1988 118-132
8. C.P. O'Brien Research advances in the understanding and treatment of addiction Am J Addict 12 Suppl 2 2003 S36-S47
9. G. Gonzalez A. Oliveto T.R. Kosten Combating opiate dependence: A comparison among the available pharmacological options Expert Opin Pharmacother 5 4 2004 713-725
10. J.M. Swanson N.D. Volkow Serum and brain concentrations of methylphenidate: Implications for use and abuse Neurosci Biobehav Rev 27 7 2003 615-621
11. W.B. Pickworth R.E. Johnson B.A. Holicky E.J. Cone Subjective and physiologic effects of intravenous buprenorphine in humans Clin Pharmacol Ther 53 5 1993 570-576
12. M. Smolka L.G. Schmidt The influence of heroin dose and route of administration on the severity of the opiate withdrawal syndrome Addiction 94 8 1999 1191-1198
13. L.A. Marsch W.K. Bickel G.J. Badger J.P. Rathmell M.D. Swedberg B. Jonzon et al. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans J Pharmacol Exp Ther 299 3 2001 1056-1065
14. R.L. Balster C.R. Schuster Fixed-interval schedule of cocaine reinforcement: Effect of dose and infusion duration J Exp Anal Behav 20 1 1973 119-129
15. L.V. Panlilio S.R. Goldberg J.P. Gilman R. Jufer E.J. Cone C.W. Schindler Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys Psychopharmacology (Berl) 137 3 1998 253-258
16. N.D. Volkow J.S. Fowler G-J. Wang W.W. Shreeve Imaging studies in substance abuse In: L.E. Feinendegen editor. Molecular Nuclear Medicine 2003 Springer-Verlag Berlin, Germany
17. G. Zernig S. Giacomuzzi Y. Riemer G. Wakonigg K. Sturm A. Saria Intravenous drug injection habits: Drug users' self-reports versus researchers' perception Pharmacology 68 1 2003 49-56
18. N.D. Volkow G.J. Wang M.W. Fischman R. Foltin J.S. Fowler D. Franceschi et al. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain Life Sci 67 12 2000 1507-1515
19. J.S. Fowler N.D. Volkow J. Logan S.J. Gatley N. Pappas P. King et al. Measuring dopamine transporter occupancy by cocaine in vivo: Radiotracer considerations Synapse 28 2 1998 111-116
20. A.N. Samaha T.E. Robinson Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 26 2 2005 82-87
21. M.C. Ko J. Terner S. Hursh J.H. Woods G. Winger Relative reinforcing effects of three opioids with different durations of action J Pharmacol Exp Ther 301 2 2002 698-704
22. A.M. Davis C.E. Inturrisi d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia J Pharmacol Exp Ther 289 2 1999 1048-1053
23. K. Lutfy S. Eitan C.D. Bryant Y.C. Yang N. Saliminejad W. Walwyn et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors J Neurosci 23 32 2003 10331-10337
24. B.L. Kieffer C. Gaveriaux-Ruff Exploring the opioid system by gene knockout Prog Neurobiol 66 5 2002 285-306
25. S. Ide M. Minami M. Satoh G.R. Uhl I. Sora K. Ikeda Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice Neuropsychopharmacology 29 9 2004 1656-1663
26. S.D. Comer E.D. Collins Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers J Pharmacol Exp Ther 303 2 2002 695-703
27. C.J. Evans Secrets of the opium poppy revealed Neuropharmacology 47 Suppl 1 2004 293-299
28. G.W. Pasternak Multiple opiate receptors: Deja vu all over again Neuropharmacology 47 Suppl 1 2004 312-323
29. M.R. Yeomans R.W. Gray Opioid peptides and the control of human ingestive behaviour Neurosci Biobehav Rev 26 6 2002 713-728
30. A.L. Vaccarino G.A. Olson R.D. Olson A.J. Kastin Endogenous opiates: 1998 Peptides 20 12 1999 1527-1574
31. C. Contet B.L. Kieffer K. Befort Mu opioid receptor: A gateway to drug addiction Curr Opin Neurobiol 14 3 2004 370-378
32. F. Berrendero V. Mendizabal P. Robledo L. Galeote A. Bilkei-Gorzo A. Zimmer et al. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene J Neurosci 25 5 2005 1103-1112
33. A. Moles B.L. Kieffer F.R. D'Amato Deficit in attachment behavior in mice lacking the mu-opioid receptor gene Science 304 5679 2004 1983-1986
34. P.D. Skoubis H.W. Matthes W.M. Walwyn B.L. Kieffer N.T. Maidment Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice Neuroscience 106 4 2001 757-763
35. P.D. Skoubis H.A. Lam J. Shoblock S. Narayanan N.T. Maidment Endogenous enkephalins, not endorphins, modulate basal hedonic state in mice Eur J Neurosci 21 5 2005 1379-1384
36. K. Miotto M. McCann J. Basch R. Rawson W. Ling Naltrexone and dysphoria: fact or myth? Am J Addict 11 2 2002 151-160
37. T.S. Shippenberg A. Herz Differential effects of mu and kappa opioid systems on motivational processes NIDA Res Monogr 75 1986 563-566
38. B.L. Roth K. Baner R. Westkaemper D. Siebert K.C. Rice S. Steinberg et al. Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist Proc Natl Acad Sci USA 99 18 2002 11934-11939
39. J. Manzanares S. Ortiz J.M. Oliva S. Perez-Rial T. Palomo Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects Alcohol Alcohol 40 1 2005 25-34
40. C. Cohen G. Perrault G. Griebel P. Soubrie Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716) Neuropsychopharmacology 30 1 2005 145-155
41. G.L. Gessa S. Serra G. Vacca M.A. Carai G. Colombo Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats Alcohol Alcohol 40 1 2005 46-53
42. A. Castane E. Valjent C. Ledent M. Parmentier R. Maldonado O. Valverde Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence Neuropharmacology 43 5 2002 857-867
43. B. Le Foll S.R. Goldberg Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence J Pharmacol Exp Ther 312 3 2005 875-883
44. T.J. De Vries W. de Vries M.C. Janssen A.N. Schoffelmeer Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A Behav Brain Res 161 1 2005 164-168
45. B. Forget M. Hamon M.H. Thiebot Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats Psychopharmacology (Berl) 2005 1-13
46. P. Murtra A.M. Sheasby S.P. Hunt C. De Felipe Rewarding effects of opiates are absent in mice lacking the receptor for substance P Nature 405 6783 2000 180-183
47. T.L. Ripley C.A. Gadd C. De Felipe S.P. Hunt D.N. Stephens Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors Neuropharmacology 43 8 2002 1258-1268
48. C.A. Gadd P. Murtra C. De Felipe S.P. Hunt Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse J Neurosci 23 23 2003 8271-8280
49. R.U. Hasenohrl P. Gerhardt J.P. Huston Naloxone blocks conditioned place preference induced by substance P and [pGlu6]-SP(6-11) Regul Pept 35 3 1991 177-187
50. N.M. Rupniak E.C. Carlson T. Harrison B. Oates E. Seward S. Owen et al. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice Neuropharmacology 39 8 2000 1413-1421
51. R.L. Solomon J.D. Corbit An opponent-process theory of motivation. I. Temporal dynamics of affect Psychol Rev 81 2 1974 119-145
52. J.M. White Pleasure into pain: The consequences of long-term opioid use Addict Behav 29 7 2004 1311-1324
53. B.B. Price S. Moran M.A. Crunican S. Rothenberg H.S. Cutter Mood, primary heroin withdrawal, and acute methadone administration Int J Addict 10 4 1975 613-631
54. G.F. Koob M. Le Moal Drug abuse: Hedonic homeostatic dysregulation Science 278 5335 1997 52-58
55. G.F. Koob Neuroadaptive mechanisms of addiction: Studies on the extended amygdala Eur Neuropsychopharmacol 13 6 2003 442-452
56. S.C. Heinrichs F. Menzaghi G. Schulteis G.F. Koob L. Stinus Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal Behav Pharmacol 6 1 1995 74-80
57. G. Aston-Jones G.C. Harris Brain substrates for increased drug seeking during protracted withdrawal Neuropharmacology 47 Suppl 1 2004 167-179
58. S.K. Sharma W.A. Klee M. Nirenberg Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance Proc Natl Acad Sci USA 72 8 1975 3092-3096
59. A.R. Gintzler S. Chakrabarti Opioid tolerance and the emergence of new opioid receptor-coupled signaling Mol Neurobiol 21 1-2 2000 21-33
60. R.Z. Terwilliger D. Beitner-Johnson K.A. Sevarino S.M. Crain E.J. Nestler A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function Brain Res 548 1-2 1991 100-110
61. R.S. Duman J.F. Tallman E.J. Nestler Acute and chronic opiate-regulation of adenylate cyclase in brain: Specific effects in locus coeruleus J Pharmacol Exp Ther 246 3 1988 1033-1039
62. M.S. Gold A.C. Pottash I.L. Extein H.D. Kleber Neuroanatomical sites of action of clonidine in opiate withdrawal: The locus coeruleus connection Prog Clin Biol Res 71 1981 285-298
63. K.T. Britton T. Svensson J. Schwartz F.E. Bloom G.F. Koob Dorsal noradrenergic bundle lesions fail to alter opiate withdrawal or suppression of opiate withdrawal by clonidine Life Sci 34 2 1984 133-139
64. T.Z. Shaw-Lutchman M. Barrot T. Wallace L. Gilden V. Zachariou S. Impey et al. Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone-precipitated morphine withdrawal J Neurosci 22 9 2002 3663-3672
65. R. Maldonado J.A. Blendy E. Tzavara P. Gass B.P. Roques J. Hanoune et al. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB Science 273 5275 1996 657-659
66. S.B. Lane-Ladd J. Pineda V.A. Boundy T. Pfeuffer J. Krupinski G.K. Aghajanian et al. CREB (cAMP response element-binding protein) in the locus coeruleus: Biochemical, physiological, and behavioral evidence for a role in opiate dependence J Neurosci 17 20 1997 7890-7901
67. B. Bie Y. Peng Y. Zhang Z.Z. Pan cAMP-mediated mechanisms for pain sensitization during opioid withdrawal J Neurosci 25 15 2005 3824-3832
68. G. Lim S. Wang J. Mao cAMP and protein kinase A contribute to the downregulation of spinal glutamate transporters after chronic morphine Neurosci Lett 376 1 2005 9-13
69. G.W. Guo Z.H. Liu W.Q. Jin H.P. Zhang X.J. Chen Y.C. Zhu et al. Quantitative comparison of ohmefentanyl isomers induced conditioning place preference in mice Life Sci 68 21 2001 2383-2390
70. B.Y. Chen W.Q. Jin X.J. Chen Y.C. Zhu Z.Q. Chi Analgesic activity and opioid receptor selectivity of stereoisomers of ohmefentanyl isothiocyanate Eur J Pharmacol 424 3 2001 195-198
71. G.A. Brine P.A. Stark Y. Liu F.I. Carroll P. Singh H. Xu et al. Enantiomers of diastereomeric cis-N-[1-(2-hydroxy-2-phenylethyl)- 3-methyl-4-piperidyl]-N-phenylpropanamides: Synthesis, X-ray analysis, and biological activities J Med Chem 38 9 1995 1547-1557
72. G.W. Guo Y. He W.Q. Jin Y. Zou Y.C. Zhu Z.Q. Chi Comparison of physical dependence of ohmefentanyl stereoisomers in mice Life Sci 67 2 2000 113-120
73. S. Eitan C.D. Bryant N. Saliminejad Y.C. Yang E. Vojdani D. Keith Jr et al. Brain region-specific mechanisms for acute morphine-induced mitogen-activated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization J Neurosci 23 23 2003 8360-8369
74. L.J. Sim D.E. Selley S.I. Dworkin S.R. Childers Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain J Neurosci 16 8 1996 2684-2692
75. A.Y. Bespalov E.E. Zvartau P.M. Beardsley Opioid-NMDA receptor interactions may clarify conditioned (associative) components of opioid analgesic tolerance Neurosci Biobehav Rev 25 4 2001 343-353
76. M.H. Ossipov J. Lai T. King T.W. Vanderah F. Porreca Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure Biopolymers 80 2-3 2005 319-324
77. S. Kayan L.A. Woods C.L. Mitchell Morphine-induced hyperalgesia in rats tested on the hot plate J Pharmacol Exp Ther 177 3 1971 509-513
78. J. Mao Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy Pain 100 3 2002 213-217
79. S. Siegel Evidence from rats that morphine tolerance is a learned response J Comp Physiol Psychol 89 5 1975 498-506
80. M.D. Krank Conditioned hyperalgesia depends on the pain sensitivity measure Behav Neurosci 101 6 1987 854-857
81. J.M. Mitchell A.I. Basbaum H.L. Fields A locus and mechanism of action for associative morphine tolerance Nat Neurosci 3 1 2000 47-53
82. A. Wikler Dynamics of drug dependence. Implications of a conditioning theory for research and treatment Arch Gen Psychiatry 28 5 1973 611-616
83. A.R. Childress A.T. McLellan C.P. O'Brien Role of conditioning factors in the development of drug dependence Psychiatr Clin North Am 9 3 1986 413-425
84. G.C. Harris G. Aston-Jones Enhanced morphine preference following prolonged abstinence: Association with increased Fos expression in the extended amygdala Neuropsychopharmacology 28 2 2003 292-299
85. P. Veinante M.E. Stoeckel F. Lasbennes M.J. Freund-Mercier c-Fos and peptide immunoreactivities in the central extended amygdala of morphine-dependent rats after naloxone-precipitated withdrawal Eur J Neurosci 18 5 2003 1295-1305
86. C. Oncken J. Van Kirk H.R. Kranzler Adverse effects of oral naltrexone: analysis of data from two clinical trials Psychopharmacology (Berl) 154 4 2001 397-402
87. M. Mas-Nieto B. Pommier E.T. Tzavara A. Caneparo S. Da Nascimento G. Le Fur et al. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: Evaluation of the interest in pharmacotherapy of opioid addiction Br J Pharmacol 132 8 2001 1809-1816
88. J.E. De Araujo J.P. Huston M.L. Brandao Place aversion induced by microinjections of C-fragment of substance P into the dorsal periaqueductal gray of rats is mediated by tachykinin NK1 receptors Peptides 22 9 2001 1447-1452
89. R. Maldonado D. Girdlestone B.P. Roques RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats Neurosci Lett 156 1-2 1993 135-140
90. J.J. Buccafusco L.C. Shuster Effect of intrathecal pretreatment with the neurokinin receptor antagonist CP-99994 on the expression of naloxone-precipitated morphine withdrawal symptoms Brain Res Bull 43 3 1997 321-326
91. N. Michaud R. Couture Cardiovascular and behavioural effects induced by naloxone-precipitated morphine withdrawal in rat: Characterization with tachykinin antagonists Neuropeptides 37 6 2003 345-354
92. L.A. Chahl P.A. Johnston Effect of the nonpeptide NK-1 receptor antagonist CP-96,345 on the morphine withdrawal response of guinea-pigs Regul Pept 46 1-2 1993 373-375
93. M. Navarro J. Chowen A.C.M. Rocio I. del Arco M.A. Villanua Y. Martin et al. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats Neuroreport 9 15 1998 3397-3402
94. R. Bals-Kubik A. Herz T.S. Shippenberg Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated Psychopharmacology (Berl) 98 2 1989 203-206
95. A.B. Sante M.J. Nobre M.L. Brandao Place aversion induced by blockade of mu or activation of kappa opioid receptors in the dorsal periaqueductal gray matter Behav Pharmacol 11 7-8 2000 583-589
96. D. Braida S. Iosue S. Pegorini M. Sala Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats Eur J Pharmacol 506 1 2004 63-69
97. P. Hyytia K. Kiianmaa Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats Alcohol Clin Exp Res 25 1 2001 25-33
98. R. Bals-Kubik T.S. Shippenberg A. Herz Involvement of central mu and delta opioid receptors in mediating the reinforcing effects of beta-endorphin in the rat Eur J Pharmacol 175 1 1990 63-69
99. K. Gulya M. Krivan N. Nyolczas Z. Sarnyai G.L. Kovacs Central effects of the potent and highly selective mu opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice Eur J Pharmacol 150 3 1988 355-360
100. H.W. Matthes R. Maldonado F. Simonin O. Valverde S. Slowe I. Kitchen et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene Nature 383 6603 1996 819-823
101. A.L. Vaccarino H. Plamondon R. Melzack Analgesic and aversive effects of naloxone in BALB/c mice Exp Neurol 117 2 1992 216-218
102. S. Ghozland H.W. Matthes F. Simonin D. Filliol B.L. Kieffer R. Maldonado Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors J Neurosci 22 3 2002 1146-1154
103. J.M. Mitchell M.T. Liang H.L. Fields A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats Psychopharmacology (Berl) 2005 1-10
104. K.M. Kovacs I. Szakall D. O'Brien R. Wang K.Y. Vinod M. Saito et al. Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice Alcohol Clin Exp Res 29 5 2005 730-738
105. S.S. Negus S.J. Henriksen A. Mattox G.W. Pasternak P.S. Portoghese A.E. Takemori et al. Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats J Pharmacol Exp Ther 265 3 1993 1245-1252
106. F. Simonin O. Valverde C. Smadja S. Slowe I. Kitchen A. Dierich et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal Embo J 17 4 1998 886-897
107. C. De Felipe J.F. Herrero J.A. O'Brien J.A. Palmer C.A. Doyle A.J. Smith et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P Nature 392 6674 1998 394-397
108. C. Ledent O. Valverde G. Cossu F. Petitet J.F. Aubert F. Beslot et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 5400 1999 401-404
109. A.H. Lichtman B.R. Martin The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats Pharmacol Biochem Behav 57 1-2 1997 7-12
110. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 2005.
111. M. Naassila O. Pierrefiche C. Ledent M. Daoust Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice Neuropharmacology 46 2 2004 243-253
112. M. Navarro M.R. Carrera W. Fratta O. Valverde G. Cossu L. Fattore et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration J Neurosci 21 14 2001 5344-5350
113. M. Solinas L.V. Panlilio K. Antoniou L.A. Pappas S.R. Goldberg The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats J Pharmacol Exp Ther 306 1 2003 93-102
114. L. Stinus M. Cador E.P. Zorrilla G.F. Koob Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats Neuropsychopharmacology 30 1 2005 90-98
115. M.F. Olive K.K. Mehmert H.N. Koenig R. Camarini J.A. Kim M.A. Nannini et al. A role for corticotropin releasing factor (CRF) in ethanol consumption, sensitivity, and reward as revealed by CRF-deficient mice Psychopharmacology (Berl) 165 2 2003 181-187
116. O. Valverde M.C. Fournie-Zaluski B.P. Roques R. Maldonado The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats Psychopharmacology (Berl) 123 2 1996 119-126
117. F. Crespi The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats Methods Find Exp Clin Pharmacol 20 8 1998 679-697
118. K. Opitz The effect of clonidine and related substances on voluntary ethanol consumption in rats Drug Alcohol Depend 25 1 1990 43-48
119. T.H. Hand L. Stinus M. Le Moal Differential mechanisms in the acquisition and expression of heroin-induced place preference Psychopharmacology (Berl) 98 1 1989 61-67
120. T. Rubino P. Massi D. Vigano D. Fuzio D. Parolaro Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome Life Sci 66 22 2000 2213-2219
121. S.C. Black Cannabinoid receptor antagonists and obesity Curr Opin Investig Drugs 5 4 2004 389-394
122. A. Holmes M. Heilig N.M. Rupniak T. Steckler G. Griebel Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders Trends Pharmacol Sci 24 11 2003 580-588
123. L.R. Gowing M. Farrell R.L. Ali J.M. White Alpha2-adrenergic agonists in opioid withdrawal Addiction 97 1 2002 49-58
124. L.P. Dwoskin B.S. Neal S.B. Sparber Yohimbine exacerbates and clonidine attenuates acute morphine withdrawal in rats Eur J Pharmacol 90 2-3 1983 269-273
125. Y. Shaham D. Highfield J. Delfs S. Leung J. Stewart Clonidine blocks stress-induced reinstatement of heroin seeking in rats: An effect independent of locus coeruleus noradrenergic neurons Eur J Neurosci 12 1 2000 292-302
126. S. Erb P.K. Hitchcott H. Rajabi D. Mueller Y. Shaham J. Stewart Alpha-2 adrenergic receptor agonists block stress-induced reinstatement of cocaine seeking Neuropsychopharmacology 23 2 2000 138-150
127. F. Noble B.P. Roques The role of CCK2 receptors in the homeostasis of the opioid system Drugs Today (Barc) 39 11 2003 897-908
128. K. Rasmussen J.F. Czachura M.J. Kallman D.R. Helton The CCK-B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle Neuroreport 7 5 1996 1050-1052
129. J. Wilson H.J. Little CCK(B) antagonists protect against some aspects of the ethanol withdrawal syndrome Pharmacol Biochem Behav 59 4 1998 967-973
130. J. Wilson W.P. Watson H.J. Little CCK(B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze Psychopharmacology (Berl) 137 2 1998 120-131
131. F. Crespi M. Corsi A. Reggiani E. Ratti G. Gaviraghi Involvement of cholecystokinin within craving for cocaine: Role of cholecystokinin receptor ligands Expert Opin Investig Drugs 9 10 2000 2249-2258
132. T. Suzuki M. Narita Y. Takahashi M. Misawa H. Nagase Effects of nor-binaltorphimine on the development of analgesic tolerance to and physical dependence on morphine Eur J Pharmacol 213 1 1992 91-97
133. R. Maldonado S. Negus G.F. Koob Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists Neuropharmacology 31 12 1992 1231-1241
134. R. Spanagel O.F. Almeida C. Bartl T.S. Shippenberg Endogenous kappa-opioid systems in opiate withdrawal: Role in aversion and accompanying changes in mesolimbic dopamine release Psychopharmacology (Berl) 115 1-2 1994 121-127
135. W. Wongchanapai B.K. Tsang Z. He I.K. Ho Relative involvement of spinal opioid receptors in physical dependence on intrathecal butorphanol and morphine Pharmacol Biochem Behav 60 4 1998 899-907
136. R.B. Rothman D.A. Gorelick S.J. Heishman P.R. Eichmiller B.H. Hill J. Norbeck et al. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence J Subst Abuse Treat 18 3 2000 277-281
137. L. Fattore M.S. Spano G. Cossu S. Deiana W. Fratta Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats Eur J Neurosci 17 8 2003 1723-1726
138. T.J. De Vries J.R. Homberg R. Binnekade H. Raaso A.N. Schoffelmeer Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats Psychopharmacology (Berl) 168 1-2 2003 164-169
139. G.F. Koob Stress, corticotropin-releasing factor, and drug addiction Ann N Y Acad Sci 897 1999 27-45
140. L. Lu M. Huang Z. Liu L. Ma Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats Neuroreport 11 4 2000 829-832
141. O. Valverde B.P. Roques Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats Neurosci Lett 244 1 1998 37-40
142. A.E. Panerai L.C. Rovati E. Cocco P. Sacerdote P. Mantegazza Dissociation of tolerance and dependence to morphine: A possible role for cholecystokinin Brain Res 410 1 1987 52-60
143. B. Pommier F. Beslot A. Simon M. Pophillat T. Matsui V. Dauge et al. Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system J Neurosci 22 5 2002 2005-2011
144. V. Kayser J.J. Idanpaan-Hekkila D. Christensen G. Guilbaud The selective cholecystokininB receptor antagonist L-365,260 diminishes the expression of naloxone-induced morphine withdrawal symptoms in normal and neuropathic rats Life Sci 62 10 1998 947-952
145. T.A. Kosten Clonidine attenuates conditioned aversion produced by naloxone-precipitated opiate withdrawal Eur J Pharmacol 254 1-2 1994 59-63
146. G. Schulteis L. Stinus V.B. Risbrough et al. G.F. Koob Clonidine blocks acquisition but not expression of conditioned opiate withdrawal in rats Neuropsychopharmacology 19 5 1998 406-416
147. P. Valeri B. Martinelli G. Pimpinella C. Severini Effects of dapiprazole, clonidine and yohimbine on the development of dependence and withdrawal behaviour in mice Drug Alcohol Depend 23 1 1989 73-77
148. J. Turchan W. Lason B. Budziszewska B. Przewlocka Effects of single and repeated morphine administration on the prodynorphin, proenkephalin and dopamine D2 receptor gene expression in the mouse brain Neuropeptides 31 1 1997 24-28
149. M.H. Ossipov J. Lai T.W. Vanderah F. Porreca Induction of pain facilitation by sustained opioid exposure: Relationship to opioid antinociceptive tolerance Life Sci 73 6 2003 783-800
150. T.W. Vanderah L.R. Gardell S.E. Burgess M. Ibrahim A. Dogrul C.M. Zhong et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance J Neurosci 20 18 2000 7074-7079
151. I. Carroll J.B. Thomas L.A. Dykstra A.L. Granger R.M. Allen J.L. Howard et al. Pharmacological properties of JDTic: A novel kappa-opioid receptor antagonist Eur J Pharmacol 501 1-3 2004 111-119
152. M.J. Kreek K.S. LaForge E. Butelman Pharmacotherapy of addictions Nat. Rev. Drug Discov 1 9 2002 710-726
153. Y. Shaham S. Erb S. Leung Y. Buczek J. Stewart CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats Psychopharmacology (Berl) 137 2 1998 184-190
154. Przegalinski E, Filip M, Frankowska M, Zaniewska M, Papla I. Effects of CP 154,526, a CRF(1) receptor antagonist, on behavioral responses to cocaine in rats. Neuropeptides 2005.
155. L. Lu B. Zhang Z. Liu Z. Zhang Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats Brain Res 954 1 2002 132-140
156. J.P. McLaughlin M. Marton-Popovici C. Chavkin Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses J Neurosci 23 13 2003 5674-5683
157. McLaughlin JP, Li S, Valdez J, Chavkin TA, Chavkin C. Social Defeat Stress-Induced Behavioral Responses are Mediated by the Endogenous Kappa Opioid System. Neuropsychopharmacology 2005.
158. D.E. Keith S.R. Murray P.A. Zaki P.C. Chu D.V. Lissin L. Kang et al. Morphine activates opioid receptors without causing their rapid internalization J Biol Chem 271 32 1996 19021-19024